Abstract |
We report the results of a randomized study to elucidate whether addition of granulocyte colony-stimulating factor ( G-CSF) to immunosuppressive therapy is valuable for the treatment of severe aplastic anemia (SAA) in adults. A total of 101 previously untreated patients (median age, 54 years; range, 19 to 75 years) were randomized to receive antithymocyte globulin (ATG) and cyclosporin A (CyA) ( G-CSF- group) or ATG, CyA, and G-CSF (G-CSF+ group). In the G-CSF+ group, the hematologic response rate at 6 months was higher (77% vs 57%; P = .03) than in the G-CSF- group. No differences were observed between the groups in terms of the incidence of infections and febrile episodes. There were no differences between the G-CSF- group and the G-CSF+ group in terms of survival (88% vs 94% at 4 years), and the development of myelodysplastic syndrome (MDS)/acute leukemia (AL) (1 patient vs 2 patients). However, the relapse rate was lower in the G-CSF+ group compared with the G-CSF- group (42% vs 15% at 4 years; P = .01). Further follow-up is required to elucidate the role of G-CSF in immunosuppressive therapy for adult SAA.
|
Authors | Masanao Teramura, Akiro Kimura, Satsuki Iwase, Yuji Yonemura, Shinji Nakao, Akio Urabe, Mitsuhiro Omine, Hideaki Mizoguchi |
Journal | Blood
(Blood)
Vol. 110
Issue 6
Pg. 1756-61
(Sep 15 2007)
ISSN: 0006-4971 [Print] United States |
PMID | 17526862
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antilymphocyte Serum
- Immunosuppressive Agents
- Granulocyte Colony-Stimulating Factor
- Cyclosporine
|
Topics |
- Adolescent
- Adult
- Aged
- Anemia, Aplastic
(drug therapy, epidemiology)
- Antilymphocyte Serum
(therapeutic use)
- Cyclosporine
(therapeutic use)
- Drug Therapy, Combination
- Female
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Japan
(epidemiology)
- Male
- Middle Aged
- Survival Rate
- Treatment Outcome
|